Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : to invest $360m in advanced manufacturing facility in Ireland

09/21/2021 | 02:12am EDT
PUBLISHED21 September 2021
21 September 2021 07:00 BST
Investment will transform development and commercialisation of new medicines

AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company's global supply network is fit for future growth.

The new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company's new medicines pipeline with speed and agility.

The $360m planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs. The project, which will provide an important boost to the local economy and to the country's life-sciences sector, was developed with the support and collaboration of Ireland's investment agency, IDA Ireland.

Micheál Martin, Taoiseach, said: "I warmly welcome today's announcement from AstraZeneca that it is to establish its first ever manufacturing facility in Ireland. This $360 million investment represents a significant commitment to Ireland and will see 100 jobs being created. In choosing Ireland as the location for its new next-generation active pharmaceutical ingredient manufacturing facility, AstraZeneca joins the very strong and successful network of global life sciences companies we have in Ireland. I wish them every success with their operations here."

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "This is a tremendously proud moment for us all at AstraZeneca and I am delighted that we are bringing this very significant investment to Dublin which, with the support of the IDA, will create highly skilled jobs, nurture the country's dynamic life sciences sector and allow for the development of high value-added medicines."

Pam Cheng, Executive Vice President, Global Operations and IT, said: "The future manufacturing of APIs for our medicines includes compounds with highly complex synthesis, requiring next generation technologies and capabilities that can respond quickly and nimbly to rapidly-changing clinical and commercial needs. This significant investment will ensure the AstraZeneca supply network is fit for the future."

The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes, contributing to the Company's Ambition Zero Carbon programme. The industry-leading, future proof design of the plant will permit the addition of capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary
AstraZeneca PLC

  • Corporate and financial


AstraZeneca plc published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 06:11:04 UTC.

© Publicnow 2021
All news about ASTRAZENECA PLC
10:00aASTRAZENECA : Credit Suisse remains its Buy rating
09:07aASTRAZENECA : Announces Winners and Recognizes Oncology Change Makers in Third Annual Canc..
08:51aASTRAZENECA : Air Malta Transports Maltese Solidarity to Rwanda; 135,690 AstraZeneca vacci..
04:44aKAROLINSKA INSTITUTET : Two COVID-19 Vaccine Doses Increase Airway Antibodies After Infect..
03:02aMODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
03:01aASTRAZENECA : Conference Chair Di Morris, AstraZeneca Invites You to Join SMi's 10th Annua..
01:55aLONDON STOCK EXCHANGE : Nearly half of FTSE 100 companies have no net-zero target, Arabesq..
01:10aASTRAZENECA : India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say
10/19ASTRAZENECA : WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 422 M - -
Net income 2021 4 868 M - -
Net Debt 2021 24 833 M - -
P/E ratio 2021 34,8x
Yield 2021 2,34%
Capitalization 187 B 187 B -
EV / Sales 2021 5,97x
EV / Sales 2022 4,83x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 120,53 $
Average target price 137,86 $
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC19.32%186 853
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.12.25%235 986